Avocado-derived lipids for use in treating leukemia
AssigneePaul Anthony SPAGNUOLO
InventorsPaul Anthony Spagnuolo, Aaron David Schimmer, Eric Alexander Lee
Life of this patent
Estimating the term…
Abstract
A method of treating a leukemia comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a compound of Formula (I) and/or (II) having the structure: OR2 R R1O n OR2 R R1O n I II wherein: 10 ---- represents a single or a double bond; R is OH when C----R is C—R, and R is O when C----R is C═R; n is 1, 3, 5 or 7; and R1 and R2 are independently hydrogen or acetyl, and/or isomers, stereoisomers or solvates thereof and/or mixtures thereof.
Claims31
A method of treating a leukemia comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) and/or (II) having the structure:
- wherein:
- represents a single or a double bond;
- R is OH when CR is C—R, and R is O when CR is C═R;
- n is 1, 3, 5 or 7;
- and
- R1 and R2 are independently hydrogen or acetyl,
- and/or isomers, stereoisomers or solvates thereof and/or mixtures thereof, preferably wherein the compound is a compound of Formula (I), more preferably wherein the compound comprises a n=5, and even more wherein compound is avocadyne, avocadyne acetate and/or avocadynone acetate or a mixture comprising avocadyne, avocadyne acetate and/or avocadynone acetate.
(canceled)
(canceled)
(canceled)
(canceled)
The method, wherein the leukemia is an acute myeloid leukemia (AML), an acute lymphoblastic leukemia (ALL), a chronic lymphocytic leukemia (CLL) or a chronic myelogenous leukemia (CML) or the leukemia cell is an AML cell, an ALL cell, a CLL cell or a CML cell.
A combination comprising chemotherapeutic, selected from cytarabine and an anthracycline, and a compound of Formula (I) and/or (II) having the structure:
- wherein:
- represents a single or a double bond;
- R is OH when CR is C—R, and R is O when CR is C═R;
- n is 1, 3, 5 or 7;
- and
- R1 and R2 are independently hydrogen or acetyl,
- or isomers, stereoisomers or solvates thereof and/or mixtures thereof, preferably wherein the compound is a compound of Formula (I), more preferably wherein the compound comprises a n=5, and even more wherein compound is avocadyne, avocadyne acetate and/or avocadynone acetate or a mixture comprising avocadyne, avocadyne acetate and/or avocadynone acetate.
-20. (canceled)
(canceled)
(canceled)
A test assay for identifying for identifying putative combinations for treating leukemia comprising:
- a. contacting a leukemia cell with a compound of Formula (I) and/or (II) having the structure:
- wherein:
- represents a single or a double bond;
- R is OH when CR is C—R, and R is O when CR is C═R;
- n is 1, 3, 5 or 7;
- and
- R1 and R2 are independently hydrogen or acetyl,
- and/isomers, stereoisomers or solvates thereof and/or mixture thereof in the presence and in the absence of a test agent;
- b. measuring the viability of the cell in the presence of the test agent and in the absence of the test agent, optionally using a MTS assay;
- c. determining if the compound of Formula (I) and/or (II) and/or isomers, stereoisomers or solvates thereof and/or mixtures thereof in combination with the test agent exhibit synergistic cytotoxicity;
- and
- d. optionally testing synergistic combinations is a second viability assay.
(canceled)
(canceled)
Dependencies are inferred from the claim text.